SSA
OMGA

Schonfeld Strategic Advisors’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,700
Closed -$24.2K – 2511
2024
Q2 		$24.2K Buy
+11,700
New +$27.6K ﹤0.01% 1997
2022
Q3 		– Sell
-13,600
Closed -$51K – 3223
2022
Q2 		$51K Buy
+13,600
New +$50.6K ﹤0.01% 2222

Other funds holding OMGA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Schonfeld Strategic Advisors's OMGA Position: Q3 2024 in Review

Schonfeld Strategic Advisors sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q3 2024, closing a stake of 11,700 shares — an estimated $24.2K sold.

Schonfeld Strategic Advisors first reported a position in OMGA in Q2 2022 and held it in 2 quarters. The position peaked at $51K in Q2 2022. 54 funds tracked by Wall St. Rank hold OMGA as of Q3 2024.

  • Schonfeld Strategic Advisors reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 11,700 Omega Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $24.2K.
  • Schonfeld Strategic Advisors first reported a position in Omega Therapeutics, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Omega Therapeutics, Inc. Common Stock position peaked at $51K in Q2 2022.
  • 54 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.